scholarly journals Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?

2010 ◽  
Vol 2 (3) ◽  
pp. 15 ◽  
Author(s):  
Martin R Farlow
Keyword(s):  
Clinical Trials ◽  
Alzheimer Disease ◽  
Apoe Genotype

scholarly journals Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease

2012 ◽  
Vol 14 (8) ◽  
pp. 742-748 ◽  
Author(s):  
J. Scott Roberts ◽  
◽  
Clara A. Chen ◽  
Wendy R. Uhlmann ◽  
Robert C. Green
Keyword(s):  
Alzheimer Disease ◽  
Apoe Genotype ◽  
Risk Education

Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab

Stroke ◽  
2021 ◽  
Author(s):  
Lukas Sveikata ◽  
Andreas Charidimou ◽  
Anand Viswanathan
Keyword(s):  
Clinical Trials ◽  
Alzheimer Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Β ◽  
High Rate ◽  
Amyloid Angiopathy ◽  
Cerebrovascular Pathology ◽  
Cerebral Amyloid

We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-β immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy’s efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.

scholarly journals Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials

2020 ◽  
Vol 26 (7) ◽  
pp. 888-900
Author(s):  
Anna Hung ◽  
Monika Schneider ◽  
Marianne Hamilton Lopez ◽  
Mark McClellan
Keyword(s):  
Clinical Trials ◽  
Alzheimer Disease ◽  
Drug Development ◽  
Phase 3

Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D.

Neurogenetics ◽  
1998 ◽  
Vol 1 (3) ◽  
pp. 223-228 ◽  
Author(s):  
M. B. Graeber ◽  
S. Kösel ◽  
E. Grasbon-Frodl ◽  
H. J. Möller ◽  
P. Mehraein
Keyword(s):  
Alzheimer Disease ◽  
Disease Patient ◽  
Apoe Genotype ◽  
Alzheimer Disease Patient

scholarly journals Alzheimer Disease and Related Dementia Resources: Perspectives of African American and Caucasian Family Caregivers in Northwest Louisiana

2020 ◽  
pp. 073346482090456
Author(s):  
Elizabeth A. Disbrow ◽  
Connie L. Arnold ◽  
Nathaniel Glassy ◽  
Collette M. Tilly ◽  
Kate M. Langdon ◽  
...  
Keyword(s):  
Clinical Trials ◽  
African American ◽  
Alzheimer Disease ◽  
Family Caregivers ◽  
Support Groups ◽  
Low Income ◽  
Research Participation ◽  
The Internet ◽  
Mixed Methods Design ◽  
Caucasian Family

We examined knowledge of Alzheimer’s disease and related dementias (ADRD), resources, and research opportunities among older African American (AA) and Caucasian caregivers. A mixed methods design integrated qualitative (focus group) and quantitative (survey) data from Northwest Louisiana. Eight focus groups (59 adults, 92% female, 78% AA, 25% rural) revealed limited knowledge. Quantitative findings from 117 ADRD caregivers (83% female, 72% AA, 30% limited heath literacy, 27% low income) indicated participants obtained information from providers (54%), friends and relatives (32%), and the internet (37%). Barriers to care were cost (24%) and lack of family agreement (17%). Few families used adult daycare (8%) or support groups (28%). Concerns about research participation were violation of privacy (30%) and fear of patient distress (27%). Distrust of doctors was minimal (3%). Findings did not vary by race. There is a need for clear, literacy-appropriate information about ADRD, caregiver resources, and clinical trials.

scholarly journals Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?

2019 ◽  
Vol 33 (2) ◽  
pp. 104-112 ◽  
Author(s):  
Joshua D. Grill ◽  
Michelle M. Nuño ◽  
Daniel L. Gillen
Keyword(s):  
Clinical Trials ◽  
Alzheimer Disease

scholarly journals Pharmacotherapy of Alzheimer Disease

2007 ◽  
Vol 52 (10) ◽  
pp. 620-629 ◽  
Author(s):  
Dennis Seow ◽  
Serge Gauthier
Keyword(s):  
Clinical Trials ◽  
Alzheimer Disease ◽  
English Language ◽  
Mini Mental State Examination ◽  
Randomized Clinical Trials ◽  
Primary Analysis ◽  
Aspartate Receptor ◽  
Asymptomatic Individuals ◽  
Post Hoc ◽  
State Examination

Objective: To systematically review published clinical trials of the pharmacotherapy of Alzheimer disease (AD). Method: We searched MEDLINE for published English-language medical literature, using Alzheimer disease and treatment as key words. No other search engine was used. Our review focused on randomized clinical trials (RCTs) and corresponding metaanalyses. Results: Although there are many RCTs for the treatment of mild cognitive impairment (MCI), none have been successful in their primary analysis. The cholinesterase inhibitors donepezil, rivastigmine, and galantamine have demonstrated efficacy in 3- to 12-month placebo-controlled RCTs assessing cognitive, functional, behavioural, and global outcomes in patients with mildly to moderately severe AD. Recent data from patients with severe stages of AD demonstrate the efficacy of donepezil on cognitive and functional measures but not on behaviour. The N-methyl-D-aspartate receptor antagonist memantine has been demonstrated to be effective in 6-month, placebo-controlled RCTs of 6 months duration assessing cognitive, functional, and global outcomes of inpatients with moderate-to-severe AD (defined as a Mini Mental State Examination score below 20). Post hoc analyses have demonstrated a benefit in regard to agitation and (or) aggression, but this needs to be confirmed in a prospective RCT across Canada. Disease-modifying treatments are being tested in mild stages of AD in 18-month RCTs with cognitive and global outcomes as primary efficacy outcomes, primarily with drugs reducing amyloid synthesis or aggregation. Successful treatment in mild stages of AD could lead to RCTs in MCI and, possibly, in genetically high-risk asymptomatic individuals. Conclusion: The significant advances in the symptomatic pharmacotherapy of AD may be followed by disease-modification treatments.

Sign in / Sign up

Export Citation Format

Share Document